Skip to main content

Table 2 Univariate and multivariate analyses of disease-free survival for initial HR-positive patients with adjuvant endocrinotherapy after surgery

From: Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy

Characteristics

N (%)

DFS

Uv

Mv

P

HR (95% CI)

P

HR (95% CI)

Age, years

 

0.181

   

 ≤ 50

146 (68.5)

 

1.00

  

 > 50

67 (31.5)

 

0.645 (0.340–1.226)

  

Initial tumor stage

 

0.649

   

 T1

38 (17.8)

 

1.00

  

 T2

107 (50.2)

0.364

1.436 (0.658–3.136)

  

 T3 or T4

68 (31.9)

0.428

1.413 (0.601–3.321)

  

Initial node status

 

0.037

 

0.481

 

 Negative

26 (12.2)

 

1.00

 

1.00

 Positive

187 (87.8)

 

4.506 (1.093–18.570)

 

1.839 (0.338–9.992)

Nuclear grade

 

0.246

   

 1 or 2

73 (34.3)

 

1.00

  

 3

55 (25.8)

 

1.475 (0.765–2.845)

  

 NA

85 (39.9)

  

Histology

 

0.877

   

 IDC

183 (85.9)

 

1.00

  

 Mixed

17 (8.0)

0.802

1.126 (0.446–2.841)

  

 Other

13 (6.1)

0.639

1.277 (0.459–3.554)

  

Initial HER2 status

 

0.618

   

 Negative

182 (85.4)

 

1.00

  

 Positive

31 (14.5)

 

1.200 (0.586–2.456)

  

Initial Ki-67 status

 

0.584

   

 < 15%

57 (26.8)

 

1.00

  

 ≥ 15%

156 (73.2)

 

1.191 (0.638–2.223)

  

NAC regimens

 

0.058

   

 Anthracycline-based

65 (30.5)

 

1.00

  

 Anthracycline- and Taxane-based

133 (62.4)

0.895

0.959 (0.512–1.797)

  

 Taxane-based

15 (7.0)

0.043

2.561 (1.032–6.357)

  

Any receptor conversion

 

0.017

 

0.031

 

 No

167 (78.4)

 

1.00

 

1.00

 Yes

46 (21.6)

 

1.995 (1.130–3.521)

 

1.881 (1.058–3.342)

Tumor size at surgery

 

0.694

   

 ≤ 2 cm

88 (41.3)

 

1.00

  

 > 2 and ≤ 5 cm

114 (53.5)

0.393

1.282 (0.725–2.267)

  

 > 5 cm

11 (5.2)

0.806

1.165 (0.344–3.944)

  

Node status at surgery

 

0.005

 

0.095

 

 Negative

49 (23.0)

 

1.00

 

1.00

 Positive

164 (77.0)

 

3.774 (1.498–9.507)

 

2.556 (0.846–7.698)

HER2 status at surgery

 

0.587

   

 Negative

184 (86.4)

 

1.00

  

 Positive

29 (13.6)

 

0.790 (0.338–1.848)

  

Ki-67 status at surgery

 

0.405

   

 < 15%

116 (54.5)

 

1.00

  

 ≥ 15%

97 (45.5)

 

1.255 (0.736–2.142)

  

Radiotherapy

 

0.031

 

0.329

 

 No

57 (26.8)

 

1.00

 

1.00

 Yes

156 (73.2)

 

2.280 (1.076–4.831)

 

1.476 (0.675–3.227)

  1. DFS disease-free survival, HR hazard ratio, CI confidence interval, Uv univariate Cox proportional hazard analyses, Mv multivariate Cox proportional hazard analyses, IDC invasive ductal carcinoma, HER2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy